CBIO Q4 2022 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$75,000-525.5% YoY

Gross Profit

-$75,000100.0% margin

Operating Income

-$11M14163.5% margin

Net Income

-$10M13659.1% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

-Infinity%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$899,201

Balance Sheet

Total Assets

$52M

Total Liabilities

$9M

Stockholders' Equity

$43M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$75,000	$17,625	-525.5%
Gross Profit	-$75,000	$17,625	-525.5%
Operating Income	-$11M	-$17M	+39.0%
Net Income	-$10M	-$17M	+41.2%